Innovative Start-up

Backed by Norcliffe Capital and spun-out from the University of Strathclyde, Aureum Diagnostics is an exciting and innovative start-up company established to continue the design, development and commercialisation of a game-changing, low-cost, Point of Care electrochemical sensor platform.

Aureum Diagnostics
Aureum Diagnostics

Proprietary Technology

Based on the company’s proprietary technology, the Aureum platform uses advanced high sensitivity electrochemical detection and assay techniques to enable rapid “sample to result” detection of a wide range of medically important disease biomarkers.

Aureum’s first platform application is an ultra-fast Covid diagnostic test that aims to deliver Point of Care market-leading levels of performance whilst maintaining the simplicity and ease of use of current lateral flow tests. Aureum has multiple additional and commercially important products in the R&D pipeline.

Experienced Leadership

CEO: Oliver Davies

Oliver has over 30 years of experience working at the cutting edge of the medical diagnostics industry. During his career, Olly has held multiple leadership positions including CEO, CTO, COO, and VP R&D within early-stage innovative VC funded start-ups and established blue-chip companies.

Working With Aureum Diagnostics

CSO: Professor Damien Corrigan

Founder of Aureum Diagnostics, Damion Corrigan is also the LGC Professor in Measurement Science for Health at the University of Strathclyde. His research is focused on developing novel electrochemical diagnostic solutions for a variety of medical challenges, including AMR, sepsis, infections disease (TB and Covid-19), liquid biopsies, wearable devices, epilepsy and endometriosis.

Chairman: Professor Steve Howell

With over twenty-five years’ life science and diagnostics experience, Steve has been instrumental in creating over a dozen life science startups and has raised in excess of £100m in financing.